— Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported earnings of $2.71 per share in the fourth-quarter 2019, vs. $2.60 per share expected.
— Total revenue rose 23% to $1.38 billion, vs. $1.31 billion expected. SOLIRIS net sales rose 11% to $3.94 billion.
— For FY20, Alexion expects revenues of $5.50 – $5.56 billion. Adjusted EPS is projected to be $10.65 to $10.85.
— ALXN stock gained 1.8% during pre-market hours immediately following the announcement.
Undoubtedly the biggest event of the week was the launch of iPhone 12, the latest in Apple's smartphone series. Pre-orders for the standard model starts Friday, while the premium version
Shares of Walgreens Boots Alliance (NASDAQ: WBA) have dropped 36% since the beginning of the year, and the stock remained in red on Friday. The company reported its fourth quarter
The Bank of New York Mellon Corporation (NYSE: BK) reported third quarter 2020 earnings results today. Total revenue of $3.8 billion dipped less than 1% versus last year. Net income